Medical imaging in new drug clinical development

Journal of Thoracic Disease

Volumn 2, Issue 4, 2010, Pages 245-252

  Wang, Yi Xiang ^a   Deng, Min ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clinical development; Clinical trials; Diagnostic radiology; Medical imaging; New drug; Pharmaceutical industry

Indexed keywords

EID: 84856959923     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2010.11.10     Document Type: Review

References (64)

1. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-31.
2. Wang YX. Medical imaging in pharmaceutical clinical trials: what radiologists should know. Clin Radiol 2005;60:1051-7.
3. Murphy PS, McCarthy TJ, Dzik-Jurasz AS. The role of clinical imaging in oncological drug development. Br J Radiol 2008;81:685-92.
4. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, editors. Clinical measurement in drug evaluation. New York: Wiley; 1995. p. 1-22.
5. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging: Realizing radiology's future. Radiology 2003;227:633-8.
6. Johnson JR, Williams G, Pazdur R. End points and United States food and drug administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11.
7. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002;20:1-10
8. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 1996;125:605-13.
9. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
10. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790-5.
11. Pien HH, Fischman AJ, Thrall JH, Sorensen AG. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today 2005;10:259-66.
12. Alpert NM, Babich JW, Rubin RH. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 1997;29:923-56.
13. Aboagye EO, Price P. Use of positron emission tomography in anticancer drug development. Invest New Drugs 2003;21:169-81.
14. Mamo D, Sedman E, Tillner J, Sellers EM, Romach MK, Kapur S. EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology (Berl) 2004;175:382-8.
15. Bergström M, Grahnén A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003;59:357-66.
16. Fischman AJ, Alpert NM, Livni E, Ray S, Sinclair I, Callahan RJ, et al. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother 1993;37:1270-7.
17. Bergström M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 2004;55:1007-12.
18. Durelli L. Dose and frequency of interferon treatment matter-INCOMIN and OPTIMS. J Neurol 2003;250:IV9-14.
19. Antoni C. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
20. Thomas AL. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003;30:32-8.
21. Christian BT, Livni E, Babich JW, Alpert NM, Dischino DD, Ruediger E, et al. Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. J Pharmacol Exp Ther 1996;279:325-31.
22. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
23. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
24. Neeman M, Dafni H. Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng 2003;5:29-56.
25. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrastenhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
26. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002;38:2079-84.
27. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8-14.
28. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
29. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
30. Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003;60:253-60.
31. Matthews B, Siemers ER, Mozley PD. Imaging-based measures of disease progression in clinical trials of diseasemodifying drugs for Alzheimer disease. Am J Geriatr Psychiatry 2003;11:146-59.
32. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
33. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002;8:40-51.
34. Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, et al. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-25.
35. Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002:59:688-94.
36. Provenzale JM, Jahan R, Naidich TP, Fox AJ. Assessment of the patient with hyperacute stroke: imaging and therapy. Radiology 2003;229:347-59.
37. Wu O, Koroshetz WJ, Ostergaard L, Buonanno FS, Copen WA, Gonzalez RG, et al. Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. Stroke 2001;32:933-42.
38. Rajaram V, Pandhya S, Patel S, Meyer PM, Goldin M, Feinstein MJ, et al. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 2004;93:32C-48C.
39. Peterfy CG. Magnetic resonance imaging of rheumatoid arthritis: The evolution of clinical applications through clinical trials. Semin Arthritis Rheum 2001;30:375-96.
40. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
41. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65.
42. Goldbach-Mansky R, Mahadevan V, Yao L, Lipsky PE. The evaluation of bone damage in rheumatoid arthritis with magnetic resonance imaging. Clin Exp Rheumatol 2003;21:50-3.
43. Kellie SJ, Chaku J, Lockwood LR, O'Regan P, Waters KD, Wong CK, et al. Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy. Eur J Cancer 2005;41:1588-96.
44. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis1999;19:221-9
45. Mimbs JW, O'Donnell M, Miller JG, Sobel BE. Detection of cardiomyopathic changes induced by doxorubicin based on quantitative analysis of ultrasonic backscatter. Am J Cardiol 1981;47:1056-60.
46. Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Viganò L. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003;9:5944-51.
47. Bach PH, Nguyen TK. Renal papillary necrosis - 40 years on. Toxicol Pathol 1998;26:73-91.
48. Lang EK, Thomas R, Davis R, Shore B, Ruiz-Deya G, Macchia RJ, et al. Multiphasic helical CT diagnosis of early medullary and papillary necrosis. J Endourol 2004;18:167-71.
49. Jackson GD, Williams SR, Weller RO, van Bruggen N, Preece NE, Williams SC, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 1994;18:57-66.
50. Peyster RG, Sussman NM, Hershey BL, Heydorn WE, Meyerson LR, Yarrington JT, et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 1995;36:93-100.
51. Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 2000;41:148-57.
52. Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005;43:303-9.
53. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003;76:S87-91.
54. Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 2005;65:7041-4.
55. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
56. Laking GR, Price PM. On the development of rational standards for nuclear response evaluation. Q J Nucl Med 2003;47:3-7.
57. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-luorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82.
58. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006;47:1059-66.
59. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-82.
60. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: Implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001;28:892-903.
61. Ory PA. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 2003;62:597-604.
62. Sahani D, Saini S, Fatuga GA, Halpern EF, Lanser ME, Zimmerman JB, et al. Quantitative measurements of medical images for pharmaceutical clinical trials: Comparison between on-site and off-site assessments. Am J Roentgenol 2000;174:1159-62.
63. Pathak SD, Ng L, Wyman B, Fogarasi S, Racki S, Oelund JC, et al. Quantitative image analysis: Software system in drug development trials. Drug Discov Today 2003;8:451-8.
64. Eckstein F, Englmeier KH. Quantitative image analysis: Software system in drug development trials. Drug Discov Today 2003;10:922-3.